NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free REGN Stock Alerts $962.49 -3.81 (-0.39%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$959.25▼$970.7950-Day Range$930.00▼$993.3552-Week Range$684.80▼$998.33Volume461,802 shsAverage Volume502,216 shsMarket Capitalization$105.64 billionP/E Ratio27.70Dividend YieldN/APrice Target$967.59 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside0.5% Upside$967.59 Price TargetShort InterestHealthy1.27% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.33Based on 18 Articles This WeekInsider TradingSelling Shares$13.12 M Sold Last QuarterProj. Earnings Growth3.72%From $38.75 to $40.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.95 out of 5 starsMedical Sector235th out of 938 stocksPharmaceutical Preparations Industry98th out of 424 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 15 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $967.59, Regeneron Pharmaceuticals has a forecasted upside of 0.5% from its current price of $962.49.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.27% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 2.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.0 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Regeneron Pharmaceuticals this week, compared to 13 articles on an average week.Search Interest25 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 127% compared to the previous 30 days.MarketBeat Follows19 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 19% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,124,641.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 3.72% in the coming year, from $38.75 to $40.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 27.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 27.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 261.17.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesMarch 17, 2024 | insidertrades.comAndrew J. Murphy Sells 5,783 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMarch 28, 2024 | benzinga.comBehind the Scenes of Regeneron Pharmaceuticals's Latest Options TrendsMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 28, 2024 | fool.comStock-Split Watch: Are These 2 Top Growth Stocks Next?March 27, 2024 | finanznachrichten.deRegeneron Pharmaceuticals, Inc.: Regeneron Provides Update on Biologics License Application for OdronextamabMarch 27, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Receives Buy Rating from Truist FinancialMarch 26, 2024 | seekingalpha.comRegeneron's Triple Threat: Eylea, Libtayo, And Dupixent DominateMarch 26, 2024 | finance.yahoo.comIs Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?March 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 26, 2024 | investorplace.com3 Biotech Stocks to Buy for the Next Bull Run: March 2024March 26, 2024 | markets.businessinsider.comRegeneron Says FDA Rejects BLA Approval For Odronextamab In Follicular LyphomaMarch 25, 2024 | finance.yahoo.comUPDATE 1-US FDA declines to approve Regeneron's blood cancer therapyMarch 25, 2024 | reuters.comUS FDA declines to approve Regeneron's blood cancer therapyMarch 25, 2024 | globenewswire.comRegeneron Provides Update on Biologics License Application for OdronextamabMarch 22, 2024 | investorplace.comHot Stocks: The 3 Best Opportunities for Investing in Weight Loss DrugsMarch 20, 2024 | finance.yahoo.comREGN Apr 2024 1040.000 callMarch 20, 2024 | benzinga.comRegeneron Pharmaceuticals Unusual Options Activity For March 20March 20, 2024 | finance.yahoo.comREGN Mar 2024 995.000 callMarch 20, 2024 | finance.yahoo.comREGN Nov 2024 1050.000 callMarch 20, 2024 | finance.yahoo.comREGN Nov 2024 620.000 putMarch 19, 2024 | finance.yahoo.comREGN Dec 2025 750.000 callMarch 19, 2024 | finance.yahoo.comREGN Jan 2026 750.000 callMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regeneron on Eylea HD Success and Innovative Obesity ProgramMarch 19, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by BrokeragesMarch 18, 2024 | reuters.comUS appeals court revives Regeneron's antitrust lawsuit against NovartisMarch 17, 2024 | finance.yahoo.comRegeneron Pharmaceuticals Insiders Sold US$26m Of Shares Suggesting HesitancyMarch 15, 2024 | ca.finance.yahoo.comREGN Mar 2024 885.000 putSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/02/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$967.59 High Stock Price Target$1,184.00 Low Stock Price Target$680.00 Potential Upside/Downside+0.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)$34.75 Trailing P/E Ratio27.71 Forward P/E Ratio24.85 P/E Growth2.77Net Income$3.95 billion Net Margins30.14% Pretax Margin32.01% Return on Equity17.61% Return on Assets13.76% Debt Debt-to-Equity Ratio0.10 Current Ratio5.69 Quick Ratio4.94 Sales & Book Value Annual Sales$13.12 billion Price / Sales8.06 Cash Flow$43.24 per share Price / Cash Flow22.27 Book Value$236.63 per share Price / Book4.07Miscellaneous Outstanding Shares109,760,000Free Float100,070,000Market Cap$105.69 billion OptionableOptionable Beta0.11 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $7MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $6.59MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.62MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $1.95MMs. Marion E. McCourt (Age 64)Executive Vice President of Commercial Comp: $1.5MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXSanofiNASDAQ:SNYGSKNYSE:GSKZoetisNYSE:ZTSAllerganNYSE:AGNView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 13,400 shares on 3/27/2024Ownership: 0.000%HighPoint Advisor Group LLCBought 1,809 shares on 3/26/2024Ownership: 0.002%PNC Financial Services Group Inc.Sold 99 shares on 3/22/2024Ownership: 0.017%Accent Capital Management LLCBought 75 shares on 3/19/2024Ownership: 0.000%B. Riley Wealth Advisors Inc.Bought 158 shares on 3/15/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals has a strong product portfolio including EYLEA injection for various eye conditions and Dupixent injection for atopic dermatitis and asthma, which have shown significant market success. The company's recent development of REGEN-COV for covid-19 has positioned it well in the fight against the pandemic, potentially leading to increased revenue and market share. Regeneron Pharmaceuticals has a solid financial standing with a market capitalization of $106.06 billion, indicating stability and growth potential. The company's consistent investment in research and development for various diseases showcases a commitment to innovation and future growth opportunities. Regeneron Pharmaceuticals' stock price has shown positive performance, with a current trading price of $966.30, reflecting investor confidence and potential for capital appreciation. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: Regeneron Pharmaceuticals operates in a highly competitive industry with constant regulatory challenges and pricing pressures, which could impact profitability and market share. The company's heavy reliance on a few key products, such as EYLEA and Dupixent, for a significant portion of its revenue poses a risk in case of any unforeseen issues with these products. Regeneron Pharmaceuticals' PEG ratio of 2.76 indicates that the stock may be overvalued compared to its growth prospects, potentially leading to limited upside for investors. The company's debt-to-equity ratio of 0.10 suggests a moderate level of debt, which could increase financial risk, especially in times of economic uncertainty or market downturns. Regeneron Pharmaceuticals' beta of 0.11 indicates low volatility compared to the market, which may result in slower price movements and potentially lower returns for investors seeking higher-risk investments. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, March 27, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com. REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 20 Wall Street analysts have issued twelve-month price targets for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $680.00 to $1,184.00. On average, they expect the company's share price to reach $967.59 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2024? Regeneron Pharmaceuticals' stock was trading at $878.29 on January 1st, 2024. Since then, REGN shares have increased by 9.6% and is now trading at $962.49. View the best growth stocks for 2024 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings data on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 17.61% and a net margin of 30.14%. The business's quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm earned $10.96 earnings per share. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), American CenturyFocused Dynamic Growth ETF (FDG) and Subversive Mental Health ETF (SANE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.11%), Vanguard Group Inc. (8.05%), Capital World Investors (4.71%), Capital International Investors (2.68%), Dodge & Cox (2.16%) and Putnam Investments LLC (1.11%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.